Vivek Subbiah: Honored to host a JAMA Oncology podcast with Hagop Kantarjian
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, posted on LinkedIn:
“Super honored to host a JAMA Oncology podcast with the one and only giant of leukemia, Dr. Hagop Kantarjian from MD Anderson Cancer Center.
Wow! Amazing podcast – just a week before Thanksgiving and the American Society of Hematology meeting.
Listen to a tour de force of all therapies in CML.
CML is the poster child for precision oncology, and we always learn a lot from this field.
The podcast is about ‘Olverembatinib After Failure of TKIs, Including Ponatinib or Asciminib: A Phase 1b/2 Randomized Clinical Trial in CML’. Hosted in American Medical Association ed Hub.”
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023